The aim of this retrospective study was to evaluate the outcome of cats treated with surgical intervention for a discrete intermediate-/high-grade gastrointestinal lymphoma prior to CHOP-based chemotherapy. Variables including sex, breed, haematocrit, white blood cell count, serum albumin concentration, clinical stage of disease, gastrointestinal obstruction and peritonitis were assessed for their effect on survival. Twenty cats met the inclusion criteria with three cats still alive at the time of data analysis. The overall median survival time (MST) was 417 days (range: 12-2962 days). The disease-free interval (DFI) was 357 days (range: 0-1585 days) with six cats still deemed in remission prior to death. Only clinical stage had a significant effect on both MST and DFI. Cats with discrete intermediate/high-grade gastrointestinal lymphoma that undergo surgical resection followed by adjuvant CHOP chemotherapy may achieve acceptable overall survival times.
Introduction
Lymphoma is the most commonly diagnosed haematopoietic tumour in cats with varying anatomic forms, the gastrointestinal tract being the most frequent primary site. 1 -4 Interestingly, the incidence of feline lymphoma (LSA) is increasing with the incidence of feline leukemia virus (FeLV) infections are decreasing within the population. 2, 5 Histologic classification of gastrointestinal LSA is categorized into low, intermediate and high grades with the clinical features of intermediate and high grade being similar in biologic characterization. 6 A recent study documented that the majority of feline gastrointestinal lymphomas are low-grade and are considered to correspond to the World Health Classification (WHO) of enteropathy-associated T-cell lymphoma (EATCL) type II. 7 High grade gastrointestinal LSA can occur as a discrete gastric, small intestinal, or colonic mass or as diffuse disease, and chemotherapy is considered the standard of care for treatment. This entails COP or CHOP-based protocols with reported response rates of 47 to 74%. 8 -10 Surgical intervention for discrete gastrointestinal LSA is often restricted to patients with an apparent obstruction or evidence of peritonitis, and in the occasional instance when a diagnosis cannot be obtained on fine needle aspiration and a larger sample is required for definitive diagnosis.
There is a paucity of information in the veterinary literature regarding cats undergoing surgical resection of a discrete gastrointestinal LSA prior to systemic chemotherapy, and no data exists regarding its impact on patient survival.
11 -14 Most reports have either focused on the efficacy of different chemotherapeutic regimes, with surgical cases reported incidentally (or representing a minority of the cases), or have confined their studies to large intestinal disease. The purpose of this retrospective study was to describe the disease-free interval (DFI) and the overall survival time (MST) of cats with discrete intermediate/-high-grade gastrointestinal LSA treated with surgical resection followed by adjuvant chemotherapy.
Materials and methods

Patients and data collection
Medical records for all cats with a histologic diagnosis of discrete intermediate-/high-grade gastrointestinal LSA that underwent exploratory laparotomy with mass excision followed by chemotherapy at multiple institutions were eligible for the study. 
Chemotherapy
Cats underwent multi-agent chemotherapy with CHOP-based protocols combining cyclophosphamide (Sandoz, Princeton, NJ, USA), doxorubicin (Sagent Pharmaceuticals, Schaumberg, IL, USA), vincristine (Hospire, Lake Forest, IL, USA), prednisolone (Qualitest Pharmaceuticals, Hunstville, AL, UDS) and L-asparaginase (KRS Global Biotechnology, Boca Raton, FL, USA). The doses and frequencies of the medications and treatments were based on previously published CHOP protocols. 9 The chemotherapeutic protocol was standardized within institutions.
Response and statistical analysis
The DFI was calculated from the date of original diagnosis (at surgery) until the date of documented relapse of disease, defined as either the development of a mass lesion in the gastrointestinal tract based upon ultrasonography, with or without cytologic confirmation of lymphoma, or the development of cytologically confirmed lymphoma in another location. Cats considered to be in remission at the time of death were censored at the last follow-up (which may have also been the date of death). Survival time was calculated from the date of surgery to the date the patient died or was euthanized. Cats alive at the last communication were censored on the last day of follow-up. Owing to small group sizes specific chemotherapy protocol used was not evaluated for effect on DFI or overall survival. Similarly, the size of the removed mass and the surgical margins were not evaluated as factors due to a lack of this information for some cats and resulting overall small sample size.
The endpoints evaluated were DFI and MST. Kaplan-Meier time-to-event curves were generated and median time-to-event (and 95% confidence intervals) determined. Each variable previously mentioned was tested for its association with DFI and MST by means of univariate Cox Proportional Hazards regression. If P < 0.30, then that factor was entered in to a multivariate Cox regression. The proportionality assumption was tested and not violated (all P > 0.30). Factors were retained if P < 0.05; all previously deleted factors were individually replaced in the final model, none were significant. Hazard ratios and 95% confidence limits were reported. Calculations were performed with SAS PROC LIFETEST and PHREG (SAS v 9.3).
Results
Patient population
A total of 20 cases were identified that met the inclusion criteria. Median age at diagnosis was 11.2 years (range: 5.9-19.2 years). Twelve cats were domestic shorthair (60%); other breeds included two Himalayans (10%), two domestic medium hair (10%), and one each of Siamese, Maine coon, Bengal and domestic longhair. Fifteen were castrated males (75%) and five (25%) were spayed females. Duration of clinical signs ranged from 2 to 106 days (median: 8 days; mean: 25.8 days). Five cats had unknown duration of clinical signs based on the records.
Variables and laboratory parameters
Results of the evaluated variables (anaemia, leukocytosis, hypoalbuminemia, peritonitis and the presence or absence of intestinal obstruction) were available with four exceptions (one unknown white blood cell count and three unknown albumin levels). Anaemia was recorded in 6 of 20 cases (30%) and leukocytosis in 5 of 19 cases (26.3%). Hypoalbuminemia was recorded in 3 of 17 cases (17.6%). Only 6 of 20 cases were tested for FeLV and FIV, and all were negative.
Clinical staging
Ten (55%) cats in this study were recorded as having an abdominal ultrasound prior to surgery, one cat (5%) only had abdominal radiographs performed preoperatively, and the records from the remaining eight cats (40%) did not have this information available. Twelve cats (60%) had thoracic radiographs performed prior to surgery. The size of the removed mass was available in six cases (30%), and the sizes ranged from 0.74 × 2.2 cm to the largest at 1 × 17 cm, respectively.
Per the described staging scheme, 11 cats (55%) had stage I disease, 8 cats (40%) had stage II disease and 1 cat (5%) had stage IV disease.
Sixteen cats (80%) were histologically classified as having intermediate grade LSA and three cats (15%) were classified as having high grade LSA. One cat had histologic evidence of both low-grade and high-grade components, and was classified as having high-grade LSA.
The location of the gastrointestinal disease was confirmed during surgery and in 12 cases (60%) additional abnormalities such as enlarged lymph nodes were sampled. Locations of the LSA included small intestinal disease only in 15 cats (75%), gastric disease only in 3 cats (15%) and colonic disease only in 2 cats (10%). One cat had both discrete intestinal disease and disease in the lymph nodes. Surgical margins were available for 9 cats (45%), and 8 of these cases (89%) had clean margins while 1 case (11%) had incomplete margins. The one cat with documented incomplete margins had stage II disease and had not had a recurrence of disease at the time of death.
Following induction with chemotherapy all cats were re-evaluated with abdominal ultrasounds at various intervals: every 3-4 months (60%; six cats in stage I, five cats in stage II and one cat in stage IV), every 6 months (15%; 3 cats in stage I), every 1-3 months (15%; two cats in stage I, one cat in stage II) and every 3-6 months (10%; two cats in stage II). A complete physical examination and blood work was performed at the time of chemotherapy administration.
Surgery
Surgical resection of disease was performed in all cases. Fifteen cats (75%) had an intestinal resection and anastomosis, two cats (10%) had a colonic resection and anastomosis and three cats (15%) had a partial gastrectomy. Intestinal obstruction was identified at surgery in 6 of 20 cases (30%) and no case had evidence of peritonitis at the time of surgery. No post-operative surgical complication occurred.
Chemotherapy
Seventeen cats (85%) received a standard CHOP protocol consisting of cyclophosphamide, doxorubicin, vincristine and prednisolone. Of these cats that received CHOP 10 (58.8%) had stage I disease, 6 (35.4%) had stage II disease and 1 (5.8%) had stage IV disease. Two cats out of the study population (10%) received cyclophosphamide, prednisolone, vincristine and L-asparaginase (L-COP). One of these cats had stage I disease and the other had stage II disease. The last cat (5%) had stage II disease and received CHOP and L-asparaginase (L-CHOP).
DFI and overall survival
The median DFI was 357 days (range: 0-1585 days) (Fig. 1) . Ten cats were recorded as relapsing with LSA prior to death, and disease was suspected or documented at various locations [intestinal (6), node (1), gastric (1), renal (1) and ocular (1)] based upon ultrasound or physical examination. Four of these cats had stage I disease (40%), five had stage II disease (50%) and one had stage IV disease (10%). Eight of these cats had intermediate grade LSA (80%) and two had high-grade LSA (20%).
The cats with more advanced stages of disease consisted of 45% of the total study population (8 cats with stage II and 1 cat with stage IV). Of these cats with stage II one cat never achieved remission and one was still alive until the time of study termination. The one cat with stage IV disease had a DFI of 4 months from the time of surgery to recurrence.
Six cats were in remission at the time of their death, and all of these cats had intermediate grade LSA. Five of these cats had stage I disease (83.3%) and one had stage II disease (16.7%).
Three cats (15%) were still alive at the study termination and re-evaluation did not document recurrence of disease. Two cats had stage I disease (66.7%) and one had stage II disease (33.3%). At the study termination these cats had survived 417, 573 and 720 days from the time of diagnosis of LSA.
Median survival time (MST) for all cats was 417 days (range: 12-2962 days), with a 95% confidence interval of 159-1229 (Fig. 2) . At 500 days post-surgery 40% of the cats were still alive. Of the variables assessed for their effect on DFI and MST, only clinical stage was found to be significant (P = 0.03; Hazard Ratio = 2.39). The risk of having progressive disease increased by a factor of 2.4 for each increase in clinical stage. Additionally, for each 1 U increase in clinical stage, the risk of dying increased two-fold.
Discussion
The purpose of this study was to determine the DFI and MST of a specific subset of cats that underwent surgery for a discrete gastrointestinal intermediate-/high-grade lymphoma, followed by adjuvant C(H)OP chemotherapy. The role of surgery for cats with gastrointestinal lymphoma currently remains unclear, and surgery usually is employed chiefly in cases with obstructive disease or peritonitis.
In this study, the DFI was 357 days and the MST was 417 days. The only evaluated variable having a significant effect on the DFI and MST was the clinical stage of the disease. This affected both parameters by increasing either the chance of death or the likelihood of a shorter remission duration with each 1 U increase in clinical stage.
The demographics of the cats in this study were similar to previous reports in that the cats were predominantly male (75%), geriatric domestic short hairs. 8,14 -18 The mean age of cats in this study was 11.2 years, which is consistent with the shift in age ranges recently noted (9-11 years). 9 Because this is a descriptive retrospective study, it is difficult to directly compare the results obtained to those of other studies. This study had specific inclusion criteria that had not previously been included in other reports, in that all cats were required to have surgical intervention for discrete intermediate to high grade gastrointestinal LSA followed by adjuvant C(H)OP protocol. The authors recognize this introduced selection bias and therefore any comparison made between this study and other studies is for perspective only.
In the literature, two studies looked specifically at gastrointestinal LSA. 12, 14 In both studies, very small numbers of cats underwent surgery to remove disease prior to chemotherapy, and the limited statistics did not demonstrate any benefit between the operated and non-operated cases. In another report examining colonic neoplasia in cats, 16 cases with LSA had a laparotomy prior to chemotherapeutic induction. 13 In these cases there was no difference in survival time with those cases that had surgery. The overall survival times for these studies specifically examining alimentary LSA were 280 days 14 and 239 days 12 , which were shorter than the MST obtained in this study.
Remission information and overall survival have been reported in general for cats with LSA based on various chemotherapeutic protocols. The most common protocols are CHOP-based and COP-based, however the use of doxorubicin, L-asparaginase and methotrexate varies between studies. The median overall survival times for these studies range from 78 to 280 days 8 -11,14,15,17,19 , all of which are lower than the observed survival time of 417 days in this study. This survival time is perhaps more comparable to the MSTs of cats that achieved complete remission in recent studies, which have been reported as being 290 to 654 days. 4, 8, 9, 19 These survival times are generally longer in duration because response to treatment and achieving complete remission has been shown to correlate with longer survival times for this disease. Similarly, the DFI of the current study (357 days) was found to be similar to the previously reported remission durations ranging from 126 to 394 days. 9,10,17 -19 The reported DFI in this study is admittedly an overestimation considering that some of the cases were in a more advanced stage of disease and therefore would have gone into remission later during the course of treatment. However, the decision was made to begin the calculation of the DFI at the time of surgery, which is when the disease burden in all cats was dramatically reduced. Therefore, while the conclusion cannot be made that surgery prior to chemotherapeutic induction will result in longer survival times, the reported MST and DFI in our subset is notable.
Clinical stage had a significant effect on DFI and MST. This finding is similar to that reported in some studies 15, 18 , but not others. 9, 12, 14 It is important to note that the majority of the cats in our study had similar clinical stages (1 or 2). It is also possible that the extent of disease and therefore clinical stage was underestimated in the cats in this study because not every abdominal organ was biopsied at surgery. A prospective study with larger numbers of cats in each clinical stage group may help to corroborate this finding.
Six cats (30%) in this study did not have recurrence of LSA at the time of their death. Because there was no documented recurrence in these cats their deaths were deemed to be due to other causes, although none had a necropsy performed. The MST in these patients was long (median: 1407 days; mean: 1580.8 days). All these cats were deceased by the time of manuscript submission with various causes of death [renal failure (2) , general decrease in quality of life (2), seizures (1) and presumed heart disease (1)]. It is interesting that five of those cats had stage I disease, and the other one had stage II disease. Surgery combined with a lower tumour burden may have contributed to the excellent survival times. While prolonged responses are not common, one study did document that long-term complete remission of several years duration is possible. 10 This study has many limitations, including the ones inherent to its retrospective nature: non-standardized diagnostic testing prior to surgery, during chemotherapy treatment and post-treatment; variable follow-up information; multiple clinicians involved in case management in different institutions; and selection bias with certain cases recommended for surgery over others. Histopathology was performed by multiple pathologists, and because of the age of many of the samples it was not possible to have all histopathology reviewed by one pathologist. The chemotherapeutic protocols were not completely standardized between the institutions, and substitutions and dosage adjustments were made on an individual case basis; however, all were considered to be standard protocols. Overall the sample size is limited and there is no control population for direct, contemporary comparison. Necropsy was not performed on any cat, including those cats that died of presumed other causes.
The data for this select subgroup is intriguing and the MST is acceptable compared with other studies describing cats treated with chemotherapy alone. A randomized, prospective study that includes a comparison group receiving chemotherapy only would be required to truly determine the benefit of surgery followed by adjuvant chemotherapy in cats with gastrointestinal LSA.
